Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1902

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Heart Failure
Interventions: Baxdrostat and dapagliflozin, Placebo and dapagliflozin; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 11,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 217
States / cities: Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 188 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Osimertinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions: Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 123 Years
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Anchorage, Alaska • Los Alamitos, California • Los Angeles, California + 16 more

Conditions: Newly Diagnosed Multiple Myeloma (NDMM)
Interventions: AZD0120, Cyclophosphamide, Fludarabine, Melphalan (part of ASCT), Lenalidomide; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2039
U.S. locations: 46
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 37 more

Conditions: Intracranial Arteriosclerosis, Stroke
Interventions: Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years and older
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 114
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more

Conditions: Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
Interventions: Trastuzumab Deruxtecan; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Basking Ridge, New Jersey + 6 more

Conditions: Primary Membranous Nephropathy
Interventions: Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Los Angeles, California • Iowa City, Iowa • Bethesda, Maryland + 2 more

Conditions: Kidney Failure
Interventions: Balcinrenone/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions: AZD5492; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 4 more

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: Camizestrant, Ribociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Deutenzalutamide, Radium-223; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 28
States / cities: Dothan, Alabama • Phoenix, Arizona • Duarte, California + 24 more

Conditions: Liver Fibrosis, Hepatic Cirrhosis
Interventions: AZD2389, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Chandler, Arizona • Tucson, Arizona • Jupiter, Florida + 15 more

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Osimertinib In EGFR Mutant Lung Cancer

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

About this AstraZeneca sponsor directory page